once a week glp-1 agonist Another Weight-Loss Trial Win for Weekly Drug Another milestone in the evolution

and Thomas, A.W

Int J Endocrinol (2018) 2018:e6920620

Nausea occurs in approximately 40% of users at therapeutic doses but is transient, peaking 12 hours post-injection and resolving within 46 hours

Two-thirds of American adults are not even getting the recommended daily allowance (RDA) for a particular nutrient, and the RDA is not sufficient to protect against deficiency diseases (such as Rickets, Beriberi, Scurvy), nor does it provide optimal nutrition

The retrospective cohort study analyzed 125,474 adults who initiated liraglutide, semaglutide, or tirzepatide to treat obesity or being overweight between 2018 and 2023

Wu X et al